August 15, 2022 /

Gene Therapy Approaches to Replace or Restore Dystrophin — PPMD 2022 Annual Conference

Gene Therapy Approaches to Replace or Restore Dystrophin

PF-06939926 – Kasia Lobello, MD (Pfizer, Inc.)
RGX-202 – Jahannaz Dastgir, DO (REGENXBIO)
scAAV9.U7-ACCA – Kevin Flanigan, MD (Nationwide Children’s Hospital)
SGT-001 – Carl Morris, PhD (Solid Biosciences)
SRP-9001 – Teji Singh, MD (Sarepta Therapeutics)


Join Our Mailing List

This field is for validation purposes and should be left unchanged.
BBB Accredited Charity logoCharity Navigator Four Star Charity logoNational Health Council Standards of Excellence Certification Program logo